Literature DB >> 22575257

Abnormal expression of transcription factor activator protein-2α in pathologic placentas.

Rachel M Sheridan1, Jerzy Stanek, Jane Khoury, Stuart Handwerger.   

Abstract

Recent studies from our laboratory have indicated that the transcription factor activator protein-2α plays a critical role in the differentiation of human villous cytotrophoblast cells to syncytiotrophoblast cells. However, little is known about the expression of activator protein-2α in placentas from pathologic pregnancies. This study compares the expression of activator protein-2α in placentas from high-risk pregnancies to gestational age-matched controls. Paracentral sections from grossly unremarkable areas of 10 placentas from each group of pregnancies complicated by mild preeclampsia, severe preeclampsia, diabetes mellitus, chronic hypertension, and fetal growth restriction and 10 control cases of placentas from normal pregnancies matched for gestational age were double immunostained for activator protein-2α and E-cadherin. The total numbers of cytotrophoblast cells and syncytiotrophoblast nuclei and the numbers of activator protein-2α-positive and activator protein-2α-negative nuclei in both of these cell types were counted by 2 pathologists blinded to disease status, in 10 representative×40 high-power fields for each placenta. Abnormal placental maturation in most of pathologic pregnancies was evidenced by a 1.5- to 1.7-fold lower expression ratio of syncytiotrophoblast cell to cytotrophoblast cell. Activator protein-2α in syncytiotrophoblast cells was lower in mild preeclampsia, diabetes mellitus, hypertension, and fetal growth restriction (P<.0001 in each instance) and was higher by 2-fold in severe preeclampsia, although this increase was not statistically significant (P=.3). Because activator protein-2α has been shown to be critical for villous cytotrophoblast cell differentiation, our findings suggest that abnormalities in the activator protein-2α cascade of transcription factors and/or signaling molecules may contribute to the pathogenesis of the abnormal maturation in placentas in certain types of high-risk pregnancies. The different pattern of activator protein-2α expression in mild and severe preeclampsia clearly suggests that these conditions may have 2 independent pathogenic mechanisms.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22575257      PMCID: PMC3433582          DOI: 10.1016/j.humpath.2012.01.011

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  29 in total

1.  Microarray analysis of trophoblast differentiation: gene expression reprogramming in key gene function categories.

Authors:  B J Aronow; B D Richardson; S Handwerger
Journal:  Physiol Genomics       Date:  2001-07-17       Impact factor: 3.107

Review 2.  How to make a placenta: mechanisms of trophoblast cell differentiation in mice--a review.

Authors:  J C Cross
Journal:  Placenta       Date:  2005-04       Impact factor: 3.481

3.  The placenta in pre-eclampsia and intrauterine growth restriction: studies on exchange surface areas, diffusion distances and villous membrane diffusive conductances.

Authors:  T M Mayhew; R Manwani; C Ohadike; J Wijesekara; P N Baker
Journal:  Placenta       Date:  2006-04-24       Impact factor: 3.481

4.  Differential expression of AP-2gamma and AP-2alpha during human trophoblast differentiation.

Authors:  B D Richardson; Y H Cheng; R A Langland; S Handwerger
Journal:  Life Sci       Date:  2001-09-21       Impact factor: 5.037

5.  Term preeclampsia is associated with minimal histopathological placental features regardless of clinical severity.

Authors:  N J Sebire; R D Goldin; L Regan
Journal:  J Obstet Gynaecol       Date:  2005-02       Impact factor: 1.246

6.  Diagnosing placental membrane hypoxic lesions increases the sensitivity of placental examination.

Authors:  Jerzy Stanek
Journal:  Arch Pathol Lab Med       Date:  2010-07       Impact factor: 5.534

7.  Activator protein-2 regulates human placental lactogen gene expression.

Authors:  B D Richardson; R A Langland; C J Bachurski; R G Richards; C A Kessler; Y H Cheng; S Handwerger
Journal:  Mol Cell Endocrinol       Date:  2000-02-25       Impact factor: 4.102

8.  Is pre-eclampsia more than one disease?

Authors:  Lars J Vatten; Rolv Skjaerven
Journal:  BJOG       Date:  2004-04       Impact factor: 6.531

Review 9.  Oxygen and placental villous development: origins of fetal hypoxia.

Authors:  J C Kingdom; P Kaufmann
Journal:  Placenta       Date:  1997-11       Impact factor: 3.481

Review 10.  Placental adaptive responses and fetal programming.

Authors:  Leslie Myatt
Journal:  J Physiol       Date:  2006-02-09       Impact factor: 5.182

View more
  5 in total

1.  ETS1 induces human trophoblast differentiation.

Authors:  Cherie A Kessler; Jerzy W Stanek; Keith F Stringer; Stuart Handwerger
Journal:  Endocrinology       Date:  2015-02-04       Impact factor: 4.736

2.  FOXO1 expression in villous trophoblast of preeclampsia and fetal growth restriction placentas.

Authors:  Rachel Sheridan; Chethan Belludi; Jane Khoury; Jerzy Stanek; Stuart Handwerger
Journal:  Histol Histopathol       Date:  2014-09-09       Impact factor: 2.303

3.  Adiponectin DNA methylation in South African women with gestational diabetes mellitus: Effects of HIV infection.

Authors:  Stephanie Dias; Sumaiya Adam; Yoonus Abrahams; Paul Rheeder; Carmen Pheiffer
Journal:  PLoS One       Date:  2021-03-22       Impact factor: 3.240

4.  Mapping cis-regulatory elements in the midgestation mouse placenta.

Authors:  Rebekah R Starks; Haninder Kaur; Geetu Tuteja
Journal:  Sci Rep       Date:  2021-11-16       Impact factor: 4.379

5.  Pivotal role of the transcriptional co-activator YAP in trophoblast stemness of the developing human placenta.

Authors:  Gudrun Meinhardt; Sandra Haider; Victoria Kunihs; Leila Saleh; Jürgen Pollheimer; Christian Fiala; Szabolcs Hetey; Zsofia Feher; Andras Szilagyi; Nandor Gabor Than; Martin Knöfler
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-01       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.